rilonacept 160 mg
IL1T-AI-0505
Phase 3 small_molecule completed
Quick answer
rilonacept 160 mg for Familial Cold Autoinflammatory Syndrome (FCAS) is a Phase 3 program (small_molecule) at REGENERON PHARMACEUTICALS, INC. with 1 ClinicalTrials.gov record(s).
Program details
- Company
- REGENERON PHARMACEUTICALS, INC.
- Indication
- Familial Cold Autoinflammatory Syndrome (FCAS)
- Phase
- Phase 3
- Modality
- small_molecule
- Status
- completed